Switzerland’s bitter-sweet news for Alzheimer’s patients
The latest Alzheimer’s drugs are viewed as breakthroughs but they aren’t able to halt the disease. Keystone Swiss medicines regulator Swissmedic was expected to approve two drugs for Alzheimer‘s disease. But in late January it only approved one, leaving patients in Switzerland with fewer treatment options than in many countries. What happened? This content was … Read more